Neuroleptic malignant syndrome associated with metoclopramide in a burn patient

Ryan Nachreiner, Jeroen Balledux, Madeline Zieger, Oscar Viegas, Rajiv Sood

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Neuroleptic malignant syndrome (NMS) is an uncommon, potentially fatal syndrome that occurs with the use of neuroleptic medications. In view of the rarity of this syndrome and the overlap with the pathophysiologic manifestations of a burn, the burn surgeon may not readily recognize NMS on presentation. We describe the case of a 27-year-old man with 15% TBSA burns who developed NMS as a result of metoclopramide use. Recognition and treatment resulted in a prompt resolution of symptoms. Initial treatment should include immediate withdrawal of all neuroleptic agents, measures aimed at decreasing body temperature, supportive care, and restoration of dopamine balance. Various authors have advocated treatment with various medications, including benzodiazepines, dantrolene, and dopaminergic agents. It is important for burn unit personnel to be aware of this syndrome because the early institution of therapy can be life saving.

Original languageEnglish
Pages (from-to)237-241
Number of pages5
JournalJournal of Burn Care and Research
Volume27
Issue number2
DOIs
StatePublished - Mar 2006

Fingerprint

Neuroleptic Malignant Syndrome
Metoclopramide
Antipsychotic Agents
Dantrolene
Burn Units
Dopamine Agents
Secondary Prevention
Body Temperature
Benzodiazepines
Burns
Dopamine
Therapeutics

ASJC Scopus subject areas

  • Emergency Medicine
  • Rehabilitation
  • Surgery

Cite this

Neuroleptic malignant syndrome associated with metoclopramide in a burn patient. / Nachreiner, Ryan; Balledux, Jeroen; Zieger, Madeline; Viegas, Oscar; Sood, Rajiv.

In: Journal of Burn Care and Research, Vol. 27, No. 2, 03.2006, p. 237-241.

Research output: Contribution to journalArticle

Nachreiner, Ryan ; Balledux, Jeroen ; Zieger, Madeline ; Viegas, Oscar ; Sood, Rajiv. / Neuroleptic malignant syndrome associated with metoclopramide in a burn patient. In: Journal of Burn Care and Research. 2006 ; Vol. 27, No. 2. pp. 237-241.
@article{9990343e4d834d5fa441affeb370b8e9,
title = "Neuroleptic malignant syndrome associated with metoclopramide in a burn patient",
abstract = "Neuroleptic malignant syndrome (NMS) is an uncommon, potentially fatal syndrome that occurs with the use of neuroleptic medications. In view of the rarity of this syndrome and the overlap with the pathophysiologic manifestations of a burn, the burn surgeon may not readily recognize NMS on presentation. We describe the case of a 27-year-old man with 15{\%} TBSA burns who developed NMS as a result of metoclopramide use. Recognition and treatment resulted in a prompt resolution of symptoms. Initial treatment should include immediate withdrawal of all neuroleptic agents, measures aimed at decreasing body temperature, supportive care, and restoration of dopamine balance. Various authors have advocated treatment with various medications, including benzodiazepines, dantrolene, and dopaminergic agents. It is important for burn unit personnel to be aware of this syndrome because the early institution of therapy can be life saving.",
author = "Ryan Nachreiner and Jeroen Balledux and Madeline Zieger and Oscar Viegas and Rajiv Sood",
year = "2006",
month = "3",
doi = "10.1097/01.BCR.0000202644.17987.3F",
language = "English",
volume = "27",
pages = "237--241",
journal = "Journal of Burn Care and Research",
issn = "1559-047X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Neuroleptic malignant syndrome associated with metoclopramide in a burn patient

AU - Nachreiner, Ryan

AU - Balledux, Jeroen

AU - Zieger, Madeline

AU - Viegas, Oscar

AU - Sood, Rajiv

PY - 2006/3

Y1 - 2006/3

N2 - Neuroleptic malignant syndrome (NMS) is an uncommon, potentially fatal syndrome that occurs with the use of neuroleptic medications. In view of the rarity of this syndrome and the overlap with the pathophysiologic manifestations of a burn, the burn surgeon may not readily recognize NMS on presentation. We describe the case of a 27-year-old man with 15% TBSA burns who developed NMS as a result of metoclopramide use. Recognition and treatment resulted in a prompt resolution of symptoms. Initial treatment should include immediate withdrawal of all neuroleptic agents, measures aimed at decreasing body temperature, supportive care, and restoration of dopamine balance. Various authors have advocated treatment with various medications, including benzodiazepines, dantrolene, and dopaminergic agents. It is important for burn unit personnel to be aware of this syndrome because the early institution of therapy can be life saving.

AB - Neuroleptic malignant syndrome (NMS) is an uncommon, potentially fatal syndrome that occurs with the use of neuroleptic medications. In view of the rarity of this syndrome and the overlap with the pathophysiologic manifestations of a burn, the burn surgeon may not readily recognize NMS on presentation. We describe the case of a 27-year-old man with 15% TBSA burns who developed NMS as a result of metoclopramide use. Recognition and treatment resulted in a prompt resolution of symptoms. Initial treatment should include immediate withdrawal of all neuroleptic agents, measures aimed at decreasing body temperature, supportive care, and restoration of dopamine balance. Various authors have advocated treatment with various medications, including benzodiazepines, dantrolene, and dopaminergic agents. It is important for burn unit personnel to be aware of this syndrome because the early institution of therapy can be life saving.

UR - http://www.scopus.com/inward/record.url?scp=33745372257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745372257&partnerID=8YFLogxK

U2 - 10.1097/01.BCR.0000202644.17987.3F

DO - 10.1097/01.BCR.0000202644.17987.3F

M3 - Article

C2 - 16566575

AN - SCOPUS:33745372257

VL - 27

SP - 237

EP - 241

JO - Journal of Burn Care and Research

JF - Journal of Burn Care and Research

SN - 1559-047X

IS - 2

ER -